753 related articles for article (PubMed ID: 32974146)
21. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
22. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
Jiang H; Sun Z; Li F; Chen Q
Front Immunol; 2022; 13():983569. PubMed ID: 36405708
[TBL] [Abstract][Full Text] [Related]
24. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
25. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
26. A Prognostic Microenvironment-Related Immune Signature
Qiu H; Li Y; Cheng S; Li J; He C; Li J
Front Oncol; 2020; 10():580263. PubMed ID: 33425732
[TBL] [Abstract][Full Text] [Related]
27. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
28. Structuring and validating a prognostic model for low-grade gliomas based on the genes for plasma membrane tension.
Li J; Lv F; Jin T
Front Neurol; 2022; 13():1024869. PubMed ID: 36408514
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis.
Yan J; Wu X; Yu J; Zhu Y; Cang S
Front Oncol; 2020; 10():570654. PubMed ID: 33240814
[TBL] [Abstract][Full Text] [Related]
30. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.
Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S
Front Genet; 2022; 13():874896. PubMed ID: 35865011
[No Abstract] [Full Text] [Related]
31. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
33. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
34. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
35. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Wang Z; Li N; Qi Z; Zhao J; Huang W
Cancer Cell Int; 2021 Jul; 21(1):342. PubMed ID: 34217320
[TBL] [Abstract][Full Text] [Related]
36. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
37. Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.
Yu J; Zhang Q; Wang M; Liang S; Huang H; Xie L; Cui C; Yu J
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33492335
[TBL] [Abstract][Full Text] [Related]
38. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
39. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
Tan S; Spear R; Zhao J; Sun X; Wang P
Front Genet; 2022; 13():905047. PubMed ID: 35832194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]